Kornimate/medical-research-clean huggingface dataset:
chronotherapy in children with chronic kidney disease

Conditions: Chronic Kidney Diseases; Hypertension

Summary: this is a pilot, crossover trial in which the investigator will determine if retiming of one anti-hypertensive medication from morning to evening can effectuate normal blood pressure dipping patterns in children and adolescents with chronic kidney disease.

normally blood pressure declines by at least 10% from daytime to nighttime. in children with chronic kidney disease (ckd), often this does not happen (termed "non-dipping"). this study is a pilot, randomized cross-over trial. the main purpose of this study is to investigate whether non-dipping can be modified with retiming of anti-hypertensives in children with ckd. this is important because in adults, non-dipping has been associated with increased cardiovascular disease risk and more rapid progression of kidney disease. thus, identification of how to modify this in children with ckd, may lead to future randomized controlled trials to evaluate whether chronotherapy improves outcomes in this population, which is at high risk for morbidity and mortality in adulthood. the primary objective of this study is to determine whether retiming of one anti-hypertensive to the evening will increase nocturnal systolic blood pressure change (%) in children with ckd, hypertension and non-dipping. the secondary objective of this study is to determine whether retiming of one anti-hypertensive to the evening will increase nocturnal diastolic blood pressure change (%) in children with ckd, hypertension and non-dipping. another secondary objective is to determine if the proportion of subjects classified as having a non-dipping pattern is significantly lower on evening dosing of anti-hypertensives.

Eligibility criteria:
inclusion criteria: * male or female child/adolescent up to 18 years of age with ckd * estimated glomerular filtration rate (egfr) of 30 to 90 ml/min/1.73 m2 * diagnosed with hypertension and on a stable dose of anti-hypertensive medication(s) for at least 3 months * non-dipping identified on abpm exclusion criteria: * history of organ transplantation, oncological disease, or dialysis * inability to complete 24-hour abpm or 24-hour urine collection * children less than 6 years of age will be excluded, as they often are unable to complete a successful abpm study (≥ 40 readings, with 1 reading per hour of sleep) * currently on diuretic medications.
repeated challenge of insufficient sleep: endothelial effects

Conditions: Repeated Short Sleep Schedule

Summary: the 24-hour-a-day, 7-day a week, work-world arrived within our lifetimes, and is here to stay. americans are working more and more, frequently at multiple jobs. the pattern of short sleep during the week followed by attempts to recover on the weekend is in common practice, but we know little of the associated health risks. what is the cost in terms of increasing known risk markers for cardiovascular disease, of repeated nights of insufficient sleep, and is this cost compounded with repetition, without adequate recovery? evidence is accumulating to suggest that short sleep duration is linked to the development of metabolic and inflammation-associated diseases, such as cardiovascular disease. mechanisms involved in the development of cardiovascular disease include impaired vascular function and inflammation. the current proposal is designed to investigate the effects of repeated periods of short nocturnal sleep duration in 4 cycles (each cycle consisting of 3 nights of 4 hours of sleep opportunity per night), and each cycle of short sleep followed by a single night of recovery sleep. vascular reactivity will be assessed using brachial artery flow mediated dilation, and microcirculatory vasodilation will be assessed using perfusion imaging techniques. the dependence of il-6 and svcam-1 as measured in peripheral circulation, on vascular function, will also be investigated.

due to work, family, social and community obligations, millions of americans cut back on sleep for several nights in a row before having an opportunity to catch up. when the opportunity does arise, it may only be for a single night, before the cycle of insufficient sleep repeats. this study investigated what happens to human biology when insufficient sleep becomes chronic and opportunities for recovery sleep are intermittent. it also investigated recovery sleep itself, and the biological processes involved in reversing the effects of an accumulated sleep deficit due to insufficient sleep duration.

Eligibility criteria:
inclusion criteria: * healthy volunteers * regular sleep-wake schedule exclusion criteria: * diseases or medical conditions, including sleep disorders * current smoking * pregnant or nursing * recent time zone travel or shift work * regular medication use * high blood pressure
confirmatory study of mt-2412 in japanese patients with type 2 diabetes (add-on study of canagliflozin)

Conditions: Type 2 Diabetes Mellitus

Summary: the purpose of this study is to evaluate the efficacy and safety of co-administration of teneligliptin (mp-513) and canagliflozin (ta-7284) once daily for 24 weeks in japanese patients with type 2 diabetes mellitus who are receiving treatment with teneligliptin and have inadequate glycemic control.


Eligibility criteria:
inclusion criteria: * men or women who are 20 - 75 years old * hba1c of ≥7.0% and \<10.5% * fpg of ≤ 270 mg/dl * patients who are under dietary management and taking therapeutic exercise for diabetes over 8 weeks before run-in period exclusion criteria: * patients with type i diabetes, diabetes mellitus resulting from pancreatic disorder, or secondary diabetes * patients with serious diabetic complications * patients with hereditary glucose-galactose malabsorption or primary renal glucosuria * patients with class iii/iv heart failure symptoms according to new york heart association (nyha) functional classification * patients with severe hepatic disorder or severe renal disorder.

Keywords: mt-2412 mp-513 ta-7284 teneligliptin canagliflozin
alliance with therapeutic entourage in support of young suicidal

Conditions: Suicide

Summary: regardless of age, the quality of hospital care, the confidence that the young can have in the health care team, joining parents are pivotal elements and influence followed. family support is all the more important as 14% of young people realize a new suicidal act within three months of hospitalization for attempted suicide, and that the essential predictors appear to be the young age and quality of intra-family relationships. the main objective of this study is to determine, through the construction of an instrument to quantify the therapeutic alliance, defined by the characteristics of the mobilization of the entourage and the mutual commitments in the care of nursing teams and the entourage, the role of early therapeutic alliance with the entourage of suicidal youth 13-40 years, whether primosuicidants or repeat offenders, on short and medium term recurrences and early mortality.


Eligibility criteria:
inclusion criteria: * patient aged 13-40 years * from male or female * supported the waning of a suicidal gesture. * speaking and writing fluent french * living in upper or lower normandy * signed informed consent form, and at least one of his parents after oral and written information about the study for minors. exclusion criteria: * age \ 40 years * do not live in the upper and lower normandy regions * detained patient * forced hospitalization * patient under guardianship * patient with severe somatic pathology (cancer, heart failure, kidney or respiratory, central neurological disorder), scalable, or likely to be life-threatening within a period of less than one year * refusal to participate in the study * inability to respond
pk and ecg determinations following 8 weeks of hybryte treatment for cutaneous t-cell lymphoma

Conditions: Cutaneous T-Cell Lymphoma/Mycosis Fungoides

Summary: to assess the blood levels of hypericin and any electrocardiogram (ecg) changes during 8 weeks of hybryte (topical hypericin ointment) photodynamic therapy.


Eligibility criteria:
inclusion criteria: * a clinical diagnosis of cutaneous t-cell lymphoma (ctcl, mycosis fungoides), stage ib or stage iia * ctcl lesions covering ≥ 10% of their body surface area exclusion criteria: * history of allergy or hypersensitivity to any of the components of hybryte * pregnancy or mothers who are breast-feeding * males and females not willing to use effective contraception * subjects with history of sun hypersensitivity or photosensitive dermatoses (e.g., porphyria, systemic lupus erythematosus (sle), sjogren's syndrome, etc.) * subjects whose condition is spontaneously improving * subjects receiving topical steroids or other topical treatments (e.g., nitrogen mustard) on index lesions for ctcl within 2 weeks of enrollment * subjects receiving systemic steroids, psoralen ultraviolet a (uva) radiation therapy (puva), narrow band ultraviolet b (uvb) light therapy (nb-uvb) or carmustine (bcnu) or other systemic therapies for ctcl within 3 weeks of enrollment * subjects who have received electron beam irradiation within 3 months of enrollment * subjects with a history of significant systemic immunosuppression * subjects taking other investigational drugs or drugs of abuse within 30 days of enrollment * subjects receiving drugs known to cause photosensitization within 2 weeks of starting hybryte therapy unless they have not had evidence of photosensitization after receiving a stable dose of the medication for a minimum of 4 weeks

Keywords: ctcl mf hypericin hybryte
a long-term monitoring study of the imt-002 patients

Conditions: Macular Degeneration

Summary: this is a 5-year study of patients implanted with the implantable miniature telescope (imt by dr. isaac lipshitz) under protocol imt-002. all patients implanted with the telescope prosthesis who enrolled in the imt-002 trial were asked to participate in this study to monitor long-term safety. patients will undergo examinations at six-month intervals up to a total of 5 years following implantation.

every 6 months, manifest refraction, visual acuity, intraocular pressure, slit lamp examination, endothelial cell density, device failures, complications and adverse events will be assessed.

Eligibility criteria:
inclusion criteria: * patients must have participated in the imt-002 trial. * patients must be able to understand and comply with the requirements of the clinical study, and be able to abide by the requirements and restrictions of the study. * patients must be able to provide voluntary informed consent, and must sign and be given a copy of the written informed consent form. exclusion criteria: * patients who have not participated in the imt-002 trial.

Keywords: macular degeneration visual impairment quality of life telescope prosthesis
gene mapping for quantitative traits

Conditions: Cardiovascular Diseases; Heart Diseases

Summary: to conduct gene mapping studies for quantitative traits.

design narrative: the study built upon existing sib-pair methods for multipoint mapping of quantitative trait loci (qtl)s. it greatly expanded upon the statistical methodology to identify and localize qtls for complex traits by merging sib-pair methods with a powerful twin design which used phenotypic data on monozygotic (identical) and dizygotic (fraternal) twins to resolve phenotypic variability into genetic and non-genetic components, and partition human quantitative genetic variation into effects due to loci on specific chromosomal regions. this quantitative methodology was applied to risk factors for cardiovascular disease -- one of the most pressing health problems in western society. population-based samples of dutch, swedish, and australian twins had been identified in previous studies, phenotypic measures on lipids, lipoproteins, and other important cardiovascular risk factors had been obtained, and blood had been banked in a valuable resource which was available for use in this study. in 500 dz twin pairs, a series of 175 highly polymorphic microsatellite markers were detected using an automated process for detecting fluorescent signals. these data were analyzed using the new statistical methods both to confirm the effects of a series of candidate loci and to test for the effects of previously unknown qtls. the study completion date listed in this record was obtained from the "end date" entered in the protocol registration and results system (prs) record.

Eligibility criteria:
no eligibility criteria
role of imaging in complications of sinusitis

Conditions: Rhinosinusitis; Intracranial Extension; Rhinosinusitis Chronic; Rhinosinusitis Acute; Fungal Sinusitis; Allergic Fungal Rhinosinusitis; Invasive Fungal Sinusitis (Diagnosis)

Summary: this study aims to assess the diagnostic performance of ct and mri in the diagnosis of complications of rhinosinusitis in comparison to clinical and operative findings.


Eligibility criteria:
inclusion criteria: * male and female patients diagnosed as sinusitis with clinically suspected complications through history and physical examination (site, onset, character of pain, constitutional symptoms, duration). exclusion criteria: * patients with absolute or relative contraindications for cross sectional imaging including; claustrophobia, metallic implants, pacemaker and prosthetic heart valves for mri.

Keywords: rhinosinusitis complicated sinusitis complications of sinusitis magnetic resonance imaging computed tompgraphy mri ct
automated quantification of dental plaque

Conditions: Dental Plaque

Summary: the study generates data that contribute to the development and validation of an automated approach to full-mouth quantification of dental plaque, based on fluorescence images and intraoral scans of teeth with disclosed and undisclosed plaque.


Eligibility criteria:
inclusion criteria: males and females ≥ 18 years old presence of at least one tooth anatomically possible to perform intraoral imaging subjects need to be able to understand and follow instructions, as well as to read and sign the informed consent form exclusion criteria: history of allergies towards any of the ingredients in the disclosing agents self-reported serious medical conditions
latin american real-world study in acute leukemia

Conditions: Acute Myeloid Leukemia; Acute Lymphoid Leukemia

Summary: the objective of the study is to describe the current epidemiology, treatment patterns, outcomes and healthcare resource use of adult patients diagnosed with relapsed/refractory (r/r) b-cell all and de novo aml in 4 latin american countries.

this is a retrospective multicenter non-interventional study using real-world data collected from medical records of newly diagnosed aml or with relapsed/refractory b-cell all diagnosed between 01 january 2015 and 31 december 2019 in 4 latin american countries: argentina, brazil, chile, and colombia. in addition, as secondary objectives, the study will also describe molecular profile, cytogenetic risk, clinical outcomes, and healthcare resource utilization of treated b-cell all r/r and aml patients.

Eligibility criteria:
inclusion criteria: * patients ≥18 years old at diagnosis * confirmed diagnosis of relapsed/refractory b-cell all or de novo aml diagnosed between 01 january 2015 and 31 december 2019 * at least 1 line of treatment for r/r b-cell all or de novo aml within the study period exclusion criteria: * patients with no medical chart available * patients with unreliable data as per investigator's opinion (e.g. excessive missing data or inconsistence data) * patients that have participated in any interventional clinical trial for relapsed/refractory b-cell all or aml at any moment * patients with secondary aml * patients with any concomitant primary malignancy * patients with acute promyelocytic leukemia (apl)

Keywords: acute myeloid leukemia acute lymphoid leukemia relapsed refractory b-cell acute lymphoblastic leukemia acute leukemia in latin america loyal study
a network & dyad hiv prevention intervention for idu's - 1

Conditions: HIV; Hepatitis

Summary: the purpose of this study is to evaluate a peer-based hiv prevention intervention that targets active injection drug users and their drug and sex partners.

hiv seroincidence among injection drug users remains high, with unprotected sexual contact substantially contributing to new hiv infections among injection drug users (idus). interventions that are culturally competent and target drug users' main sex and drug partners may be especially effective for hiv/sti and hcv control and prevention. the intervention to be tested in this study draws upon theoretical and empirical evidence suggesting that peer educator programs can have significant effects on the risk-related behaviors of both the educators and the peers whom they educate. specifically, through group and individual focused sessions, participants learn and practice skills designed to reduce drug and sex related risk behaviors. furthermore, individuals and their main risk partners attend a training session that focuses on risk reduction within their relationship.

Eligibility criteria:
inclusion criteria: (i)self reported injection drug use within the prior 6 months; (ii)willingness to invite a risk network member into the study and to talk about hiv prevention; (iii)age 18 or older exclusion criteria: * not concurrently enrolled in another hiv prevention intervention

Keywords: hiv prevention intervention, injection drug user,peer-oriented, randomized controlled trial, social network
sinecort pilot efficacy study

Conditions: Atopic Dermatitis

Summary: the study shall prove whether treatment of atopic dermatitis is equally effective with sinecort cream as compared to standard therapy (hydrocortisone cream).


Eligibility criteria:
inclusion criteria: * male or female caucasians aged between 18 and 65 years * patients with mild ad presenting a scoring ad (scorad) rating between 3-25 * skin type i - iv according to fitzpatrick * acute ad symptoms on each assessment areas (local scorad \>/=3 and \<= 12) * acute symptom of pruritus at baseline exclusion criteria: * any other skin disease at the test area that would interfere the clinical assessment in the opinion of the investigator * moles, tattoos, strong pigmentation, or scars at the test area that would interfere the clinical assessment * regular intake of antiphlogistic drugs (for example, nsaids) * any condition or treatment which might influence the trial (e.g. any treatment with topical antibiotics, antifungals, or corticoids) within 14 days prior to screening as well as during the trial (exception: topical treatment of ad lesions other than the test areas (for example, face) with low potency steroids restricted to small areas) * uv-therapy or the use of solarium within 30 days before screening as well as during the trial * any alternative treatment of ad (e.g. acupuncture, kinesiology, and homoeopathy) within 30 days before screening as well as during the trial

Keywords: sinecort hydrocortison mild atopic dermatitis efficacy, safety
aluminum foil reflector on phototherapy for newborn with jaundice

Conditions: Newborn Jaundice

Summary: hyperbilirubinemia is defined as the presence of bilirubin in the serum of newborns at levels exceeding the normal range. it is the most common problem among healthy newborns, with an incidence of approximately 40% to 60% in full-term infants. the primary cause is the immature bilirubin metabolism in newborns, leading to the accumulation of excess bilirubin in the blood, which in turn results in a temporary yellowing of the skin and sclera, known as jaundice. physiological jaundice in full-term newborns typically appears 24 to 72 hours after birth, peaking on days 4 to 5. studies have shown that neonatal jaundice is a leading cause of readmission after discharge. phototherapy is the most effective and safest treatment for neonatal hyperbilirubinemia. it takes advantage of bilirubin's sensitivity to light, converting bilirubin into water-soluble conjugated bilirubin, which is then excreted through bile and urine, thereby reducing total bilirubin levels. the most effective light during phototherapy has a wavelength of 400 nm to 520 nm and an intensity of at least 30 microw/cm²/nm, with at least 80% of the infant's body surface area exposed. this study aims to investigate whether using aluminum foil reflective covering around the phototherapy incubator can enhance the effectiveness of light treatment for jaundice in infants, thus potentially reducing the duration of phototherapy required.


Eligibility criteria:
inclusion criteria: 1. newborns who are admitted to the neonatal ward for examination and treatment due to jaundice levels reaching the treatment threshold. 2. term babies below 14 days of age (gestational age of 37 weeks or greater). 3. no evidence of hemolysis exclusion criteria: 1. infants with serum bilirubin levels close to the exchange transfusion limit 2. hemolytic disease (ex: g6pd) 3. congenital anomalies 4. elevated direct bilirubin 5. infants with abnormal liver function or biliary structure 6. infants who receive cardiopulmonary resuscitation after birth or suspected perinatal asphyxia

Keywords: aluminum foil reflector phototherapy newborn hyperbilirubinemia
evaluating endometriosis with 16α-(18)f-fluoro-17β-estradiol ([f-18] fes) pet/mri

Conditions: Endometriosis

Summary: researchers are trying to improve the detection of endometriosis using f-18 fes pet/mri imaging.


Eligibility criteria:
inclusion criteria: - premenopausal women (18-50) with endometriosis exclusion criteria: * postmenopausal women * ap diameter when lying supine greater than 32 cm (too large for pet/mri) * unable to undergo pet/mri for any reason (metal implants, severe claustrophobia) * unable to receive iv gadolinium contrast for any reason (renal failure egfr \< 60, contrast allergy) * pregnant (urine test will be provided for all patients)
the need of fiberoptic bronchoscopy for placing an endobronchial blocker

Conditions: Neoplasms, Pulmonary; Thoracic Diseases

Summary: the need of fiberoptic bronchoscopy for placing an endobronchial blocker. endobronchial blockers (ebb) have been presented effective and safe alternative for lung separation in vedio-assisted thoracoscopic (vats) operations. in this study, the investigators will randomize the patients receiving vats operation with ebb into two groups: one group will receive the conventional bronchoscopic guided ebbs placement, the other group receive two step procedure without confirmation by fiberoptic bronchoscopy.

the need of fiberoptic bronchoscopy for placing an endobronchial blocker. endobronchial blockers (ebb) have been presented effective and safe alternative for lung separation in vedio-assisted thoracoscopic (vats) operations. however, there were previous reports showed that it takes longer time to position the ebb versus the double lumen tubes. placing ebbs need three-step procedure (one is placing an endotracheal tube, the second is inserting the ebb, the third is confirmation of the position by fiberoptic bronchoscopy). in this study, the investigators will randomize the patients receiving vats operation with ebb into two groups: one group will receive the conventional 3-step procedure, the other group receive two step procedure without confirmation by fiberoptic bronchoscopy.

Eligibility criteria:
inclusion criteria: lung separation by endobronchial blockers exclusion criteria: lung separation by conventional double lumen tube lung separation with endobronchial blockers through

Keywords: endobronchial blocker lung separation vedio-assisted thoracic operation